Vaxil Announces Non-Brokered Private Placement

Executive Summary

• Vaxil Bio Ltd. announced a non‑brokered private placement of up to 2,456,140 units at $0.1425 per unit, targeting gross proceeds of up to $350,000.
• Each unit consists of one common share and one common share purchase warrant; warrants allow acquisition of shares at $0.19 for five years.
• Net proceeds will be used for general corporate purposes; the offering is expected to close around November 14 2025, subject to TSX Venture Exchange approval.

Key Details

• Units Offered: Up to 2,456,140 units.
• Price per Unit: $0.1425.
• Gross Proceeds Target: Up to $350,000.
• Unit Composition: 1 common share + 1 common share purchase warrant (exercise price $0.19, five‑year term).
• Finder Compensation: Cash commission up to 8% of gross proceeds plus non‑transferable finder warrants equal to up to 8% of the aggregate number of units issued.
• Holding Period: Units, shares, and warrants subject to a four‑month‑plus‑one‑day hold period from issuance under applicable securities laws.
• Closing Timeline: Anticipated closing on or about November 14 2025, contingent upon TSX Venture Exchange approval and other customary conditions.
• Use of Proceeds: General corporate purposes.

Notable Quotes

(No direct quotes were provided in the release.)